Biotech Values

[DewDiligence]

MNTA: if one of the worst-case scenarios unfolds and [NVS] is asked to run a trial comparing its generic Lovenox to the branded one, has it been spelled out how the expenses of such a trial would be split with NVS?

I presume you’re referring to a hypothetical clinical trial intended to demonstrate safety and efficacy of m-enoxaparin rather than merely its pharmacokinetic equivalence to Lovenox. Under your hypothetical scenario, NVS would be solely responsible for the clinical-trial costs; however, NVS’ responsibility to pay such costs is probably moot because I would expect NVS to terminate the Lovenox collaboration for lack of commercial viability.